Insmed Inc at JPMorgan Healthcare Conference Transcript
Hello, everyone. Thank you for joining us. On behalf of JP Morgan team, it's my pleasure to introduce our next speaker, Will Lewis, Chairman and CEO of Insmed. Please note that we will be hosting a Q&A session in the Yorkshire room, down the hall.
With that, I will hand it over to Will. Thank you.
Thank you very much, and good morning, everyone. Before we begin, I want to draw your attention to our public filings. I'll be making some forward-looking statements, and these should be placed in the context of those public filings. In addition, I'm very pleased to also draw your attention to our label for our lead product, ARIKAYCE. These are the specific details regarding its conditionally approved use.
Our mission at Insmed is to transform the lives of patients with serious and rare diseases. And we start today's presentation, coming off of what is unquestionably the best year in Insmed's history. 2019 set all kinds of records for us, and 2020 promises to be
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |